Patient controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26593

Enrollment

Registered

2006-04-12

Start date

2004-10-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaso-occlusive crisis in sickle cell disease.

Interventions

Patient controlled analgesia versus continuous infusion of morphine.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Sickle cell disease defined as HbSS, HbSC or HbSâ (by electropheresis); 2. Age > 17 years; 3. The presence of typical pain recognized by patients as originating from vaso-occlusive crisis and which can not be explained by other causes; 4. Severe pain necessitating treatment with intravenous morphine; 5. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients already recieving opioids for more than 24 hours at time of randomization; 2. Allergy or intolerance for morphine; 3. Pregnancy; 4. Chronic use of opinoids.

Design outcomes

Primary

Measure	Time frame
1. Pain intensity; 2. Side-effects; 3. Morphine dosage.	—

Secondary

Measure	Time frame
1. Lenght of treatment; 2. Hospital stay; 3. Quality of life.	—

Contacts

Public ContactB.J. Biemond

Academic Medical Center (AMC), Department of Clinical Chemistry, P.O. Box 22660

b.j.biemond@amc.uva.nl+31 (0)20 5667391

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)